



COLORADO

Department of Health Care
Policy & Financing

Drug Utilization Review Board MEETING AGENDA

February 7, 2023

Open Session 1:00 pm to 5:00 pm

Zoom Link will be posted prior to the meeting at
<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

Health First Colorado, Colorado's Medicaid program

DUR Board Members	DUR Team
Alison Shmerling, MD, MPH (Chair)	Jeffrey Taylor, PharmD (HCPF)
Liza Claus, PharmD (Vice Chair)	Rachele Poissant, PharmD (HCPF)
Todd Brubaker, DO	Veronia Guirguis-Garcia, PharmD (HCPF)
Brian Jackson, MD, MA	Julia Rawlings, PharmD (CO-DUR)
Shilpa Klocke, PharmD	Robert L Page II, PharmD, MSPH (CO-DUR)
Patricia Lanius, BSPHarm, MHA	Gina Moore, PharmD, MBA (CO-DUR)
Kenneth MacIntyre, DO	Heather Anderson, PhD (CO-DUR)
Ingrid Pan, PharmD	Garth Wright, MPH (CO-DUR)
Melissa Polvi, RN, BA (<i>Industry Representative</i>)	Nicholas Mendola, MPH (CO-DUR)

1. Call to Order
2. Roll Call and Introductions
3. Virtual Meeting Information, General Announcements, Board Chair and Vice Chair Elections
4. Colorado Department of Health Care Policy and Financing Updates
5. Final Approval of Minutes from the November 8, 2022 Meeting
6. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest

Presentations:

- Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist Jeffrey Taylor at jeffrey.taylor@state.co.us
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours prior to the start of the meeting.

7. Clinical Updates and General Orders

- FDA New Product & Safety Updates
- Quarterly Module Summaries
- Retrospective DUR Reports
- Quarterly Drug Utilization Reports

8. New Business (open for public testimony and DUR Board review)**A. Proposed Coverage Criteria for Preferred Drug List (PDL) Drug Classes**(Current PDL available for reference at <https://hcpf.colorado.gov/pharmacy-resources#PDL>)

- Opioids - Short-Acting, Fentanyl Preparations, Long-Acting
- Anticonvulsants, Oral
- Newer Generation Antidepressants
- Neurocognitive Disorder Agents
- Sedative Hypnotics
- Skeletal Muscle Relaxants
- Stimulants and Related Agents
- Triptans, Ditans and Other Migraine Treatments - Oral & Non-Oral
- Multiple Sclerosis Therapies - Disease Modifying & Symptom Management
- Ophthalmics, Immunomodulators

Mass review drug classes*

- Non-opioid Analgesia Agents - Oral & Topical
- Non-steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral
- Monoamine Oxidase Inhibitors (MAOIs)
- Tricyclic Antidepressants (TCAs)
- Anti-Parkinson's Agents
- Benzodiazepines (Non-sedative hypnotic)
- Anxiolytics, Non-Benzodiazepine
- Atypical Antipsychotics - Oral & Topical
- Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- Lithium Agents
- Ophthalmics, Allergy
- Ophthalmics, Anti-Inflammatories
- Ophthalmics, Glaucoma

** Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.*

B. Proposed Coverage Criteria for Non-PDL Products Managed Under the Pharmacy Benefit

- Dartisla (glycopyrrolate)
- Spevigo (spesolimab)
- Tarpeyo (budesonide)
- Relyvrio (sodium phenylbutyrate/taurursodiol)

C. Review of Proposed Changes to “High Cost Claims” Prior Authorization(Current Appendix P available for reference at <https://hcpf.colorado.gov/pharmacy-resources#PDL>)**9. Adjournment**

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator or send an email to hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.